Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.72 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273970 | 0.98 | PTGS2 (0.75) | PTGS2MTNR1AMTNR1BALDH1A1LMNA | |
| SCHEMBL4266887 | 0.98 | PTGS2 (0.75) | PTGS2MTNR1AMTNR1BALDH1A1LMNA | |
| SCHEMBL4404145 | 0.98 | PTGS2 (0.75) | PTGS2MTNR1AMTNR1BALDH1A1LMNA | |
| SCHEMBL4410750 | 0.98 | PTGS2 (0.75) | PTGS2MTNR1AMTNR1BALDH1A1LMNA | |
| SCHEMBL11603765 | 0.95 | PTGS2 (0.66) | PTGS2MTNR1AMTNR1BALDH1A1LMNA | |
| SCHEMBL7751 | 0.89 | MTNR1A (0.61) | PTGS2MTNR1AMTNR1BALDH1A1LMNA | |
| SCHEMBL29515347 | 0.89 | MTNR1A (0.61) | PTGS2MTNR1AMTNR1BALDH1A1LMNA | |
| SCHEMBL13668910 | 0.88 | MTNR1A (0.61) | PTGS2MTNR1AMTNR1BALDH1A1POLB | |
| SCHEMBL20545058 | 0.85 | MTNR1A (0.58) | PTGS2MTNR1AMTNR1BALDH1A1POLB | |
| SCHEMBL21102177 | 0.84 | MTNR1A (0.53) | PTGS2MTNR1AMTNR1BALDH1A1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046736-B1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2019-06-12 | — | — | EP | claimed |
| EP-2046736-B1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-2046736-B1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180334430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2018-11-22 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK A/S (DK) | 2009-10-15 | — | — | US | disclosed |
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK A/S (DK) | 2009-10-15 | — | — | US | disclosed |
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK A/S (DK) | 2009-10-15 | — | — | US | disclosed |
| EP-2046736-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008014430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008014430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB7, ABCB4, PAICS | PTGS2 2639/4885MTNR1A 1551/4885MTNR1B 958/4885 |
| US-20180334430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB7, ABCB4, PAICS | PTGS2 2639/4885MTNR1A 1551/4885MTNR1B 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.